Ms. Yarno has served as a member of GBT’s board of directors since December 2017. She has more than 25 years of experience in the biopharmaceutical industry, including at Merck & Co., Inc., where she held positions of increasing seniority, most recently as chief marketing officer. In that position, she led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as general manager, Cardiovascular/Metabolic U.S. Business Unit, and as Merck’s senior vice president of human resources. Earlier in her career, she was vice president of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary. Ms. Yarno has served as a member of the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Adial Pharmaceuticals, Durata Therapeutics and PluroGen Therapeutics. Currently, she is a member of the boards of Alder BioPharmaceuticals, Inovio Pharmaceuticals and MyoKardia. Ms. Yarno received a B.S. in business administration from Portland State University and an M.B.A. from Temple University, Fox School of Business.